Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2016 Jan;11(1):67-73.
doi: 10.1097/COH.0000000000000222.

The preexposure prophylaxis revolution: from clinical trials to routine practice: implementation view from the USA

Richard Elion  1 , Megan Coleman
Affiliations
Review

The preexposure prophylaxis revolution: from clinical trials to routine practice: implementation view from the USA

Richard Elion et al. Curr Opin HIV AIDS. 2016 Jan.

Abstract

Purpose of review: This article describes the use of tenofovir/emtricitabine (Truvada) as prevention for exposure to HIV [preexposure prophylaxis (PrEP)] infection in the USA. The use of PrEP and the challenges of implementation are very instructive as other countries adopt this intervention and it becomes a fundamental part of worldwide efforts for HIV prevention and much can be learned from the first 3 years in the USA.

Recent findings: Randomized trials and demonstration projects have shown the benefits of PrEP for men and women who are at risk for HIV. Numerous studies have showed that the level of prevention is excellent when the drug is taken at least four times weekly, once adequate levels are obtained. However, adherence remains a critical issue as well as tailoring delivery models for specific populations. Six recent studies are discussed, that support excellent efficacy and significantly support PrEP as a means of prevention. These projects have shown high acceptance of PrEP with excellent adherence by individuals demonstrated by those at risk remaining free of HIV over extended periods of time.

Summary: The USA faces three significant challenges in scaling up PrEP. The first challenge in implementation in the USA is to get individuals to recognize the actual risks that their behaviors represent and to engage with providers to address these issues. The second challenge is getting a population of providers to recognize the exact same issues and offer PrEP in a compassionate, nonjudgmental fashion. The third challenge is identifying the set of providers and locations to scale-up the response in a timely, cost-effective fashion.

PubMed Disclaimer

References

    1. US Food and Drug Administration. FDA approves first drug for reducing the risk of sexually acquired HIV infection. 2012 http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm312210.htm.
    1. Grant RM, Lama JR, Anderson PL, McMahan V, Liu AY, Vargas L, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med. 2010;363:2587–99. - PMC - PubMed
    1. Grant RM, Anderson PL, McMahan V, Liu A, Amico KR, Mehrotra M, et al. Uptake of pre-exposure prophylaxis, sexual practices, and HIV incidence in men and transgender women who have sex with men: a cohort study. Lancet Infect Dis. 2014;14:820–9. Outstanding (Excellent description of open label experience after IPREX was closed and allows close analysis of PK levels of drug associated with prevention.) - PMC - PubMed
    1. McCormack S, Dunn D. Pragmatic open-label randomised trial of preexposure prophylaxis: the PROUD STUDY; Conference on Retroviruses and Opportunistic Infections (CROI); 2015 February 23-26; Seattle, WA. 2015. Abstract 22LB.
    1. Molina JM, Capitant C, Spire B. On demand PrEP with oral TDF-FTC in MSM: results of the ANRS Ipergay trial; Conference on Retroviruses and Opportunistic Infections (CROI); 2015 February 23-26; Seattle, WA. Abstract 23LB.

Publication types

MeSH terms

Substances